All posts tagged: 12.8m

Oxford spinout Infinitopes raises £12.8m to enhance antigen discovery tech

Oxford spinout Infinitopes raises £12.8m to enhance antigen discovery tech

Infinitopes Precision Immunomics, an integrated cancer biotech, has completed a £12.8 million seed funding round led by Octopus Ventures. The round was ‘heavily oversubscribed’ and drew funds from Cancer Research Horizons, Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital, Manta Ray, Martlet Capital, Meltwind Advisory, Saras Capital and Wilbe Capital among others. This latest investment will help accelerate Infinitopes’ installation of new mass spectrometer equipment, enhancing the company’s proprietary tumour antigen discovery and computational immunobiology/AI/machine learning techniques as it looks to treat five more cancers. Since spinning out from Oxford University in 2021, Infinitopes has sought to overcome three key challenges in the field of cancer vaccines. Firstly, using its antigen discovery technologies, the firm identifies and ranks tumour signatures, enabling the accurate selection of novel, synergistic tumour targets. Secondly, it’s working to develop safe and effective proprietary vector delivery systems, capable of stimulating durable T-cell responses necessary to prevent the recurrence of life-threatening cancer metastases. Finally, Infinitopes leverages its deep knowledge of immunology and works with key opinion leaders in order to optimally schedule …